The one area where a cannabinoid crossed the full distance: anecdote → controlled trials → approved medicine.
Epidiolex (purified CBD) won FDA and EMA approval for Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex after randomized placebo-controlled trials showed meaningful seizure reductions. This is the gold-standard path, completed.
CBD epilepsy trials, PubMed ↗Median convulsive-seizure reductions in the pivotal trials ran around 40–50% versus ~15–25% on placebo. Life-changing for many families, but "reduction" not "cure" is the honest frame.
Seizure reduction magnitude, PubMed ↗Trial results come from a standardized pharmaceutical preparation at 10–20 mg/kg/day. Market CBD products vary wildly in actual content and deliver far lower doses, families substituting them for Epidiolex are not running the same experiment.
CBD product content variability, PubMed ↗The completed trials concentrate on severe pediatric syndromes. Evidence for CBD in common adult focal epilepsy is promising but not yet approval-grade; trials are ongoing.
CBD adult focal epilepsy, PubMed ↗Cannabis is not an approved treatment for epilepsy in most jurisdictions, and nothing here recommends using it. If epilepsy affects your life, bring this research, literally, these sources, to a physician and decide together. Laws differ by country and state; check CannabisLaws.ai before anything else.
Is it legal where you live? Tell us your city to see the law status and minimum age.
Status for all 64 jurisdictions on CannabisLaws. Not legal advice.